Navigation Links
Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial
Date:6/16/2008

e assessment of the potential relationship between germline and/or tumor DNA sequence alterations and the efficacy of XL184, as well as assessment of pharmacodynamics and pharmacokinetics of XL184. It is expected that approximately 100 sites in 20 countries will participate in this study.

"We are very encouraged by the level of clinical activity in the ongoing XL184 phase 1 study showing a high response rate and durable disease control in medullary thyroid cancer patients, and believe that the FDA-approved phase 3 study design will allow us to rigorously evaluate the clinical benefit of XL184 in this population for which no standard of care is available," said Gisela Schwab, MD, executive vice president and chief medical officer at Exelixis.

The planned initiation of this phase 3 trial is based on encouraging data that were presented earlier this month at the 2008 annual meeting of the American Society of Clinical Oncology (ASCO). Safety and clinical activity data were presented from an ongoing phase 1 trial of XL184 in 69 patients with various solid tumors, including 17 response-evaluable patients with MTC. These data showed a disease control rate (percentage of patients with partial responses or prolonged stable disease >3 months) of 100% in the evaluable MTC patients, with 53% of those patients (9 of 17) experiencing partial responses. The median duration of partial responses and stable disease for patients with MTC has not been reached (range 1+ to 22+ months). Most of the MTC patients in the trial had previously failed other treatments, including tyrosine kinase inhibitors with anti-RET activity (e.g., vandetanib, sorafenib, or motesanib), chemotherapeutic agents, immunotherapy, radioactive iodine, and radiotherapy.

Several additional studies with XL184 have recently been initiated to complement the planned pivotal trial in patients with MTC as part of Exelixis' strategy to rapidly advance compounds into areas of high unmet medical need whi
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Exelixis Announces June 19 Webcast of Presentation at the William Blair 28th Annual Growth Stock Conference
2. Exelixis Receives $150 Million Funding Commitment From Deerfield Management
3. Exelixis Announces June 5 Webcast of Conference Call Regarding Its $150 Million Funding Commitment from Deerfield Management
4. Exelixis Announces June 10 Webcast of Presentation at the Goldman Sachs 29th Annual Global Healthcare Conference
5. REMINDER: Exelixis Will Webcast Its June 2 Investor and Analyst Briefing at ASCO
6. Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing
7. Exelixis Announces May 13 Webcast of Presentation at the Bank of America Health Care Conference
8. Exelixis Announces May 6 Webcast of Its First Quarter 2008 Financial Results and Business Update Conference Call
9. Exelixis Announces April 30 Webcast of Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
10. Seven Abstracts Featuring Exelixis Compounds Accepted for Presentation at 2008 ASCO Annual Meeting
11. Option to Develop Exelixis Compound Exercised By Genentech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today announced ... a leading Russian pharmaceutical company, to develop and commercialize ... Federation , Turkey and ... a novel antibiotic for the treatment of bacterial infections ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of ... regulatory, business, and media events in the United States ... former associate Virginia Cox , JD, is returning to the ... Virginia Cox re-joins 3D after more than two years of ...
(Date:1/14/2014)... and BETHESDA, Md. , ... joining together with two institutes from the National Institutes ... tools for bringing safer, more effective treatments to patients ... National Center for Advancing Translational Sciences (NCATS) and the ...
(Date:1/14/2014)... Global Record Systems, LLC, (GRS), a ... for patients, physicians, the biopharmaceutical industry, regulators, payers, ... signing of a three-year Research Collaboration Agreement (RCA) ... This initiative is designed to generate disruptive ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... trying to justify RFID investment wholly on the basis ... in their supply chain are merely deluding themselves. In ... these areas, it means that gross inefficiencies exist in ... improvements even without applying RFID. , ,The benefits of ...
... Software is partnering with Brooktrout Technology to ... , ,The addition of Brooktrout TR1034 intelligent fax boards to ... integrate real-time fax over IP with their VoIP networks, allowing ... and migrate to an IP-based system in the future as ...
... Care , a not-for-profit network of healthcare services in ... NetScaler, Inc. , for a new high-performance network. ... usage and response time across its network of more ... care clinics, home health care services. , ,System architect ...
Cached Biology Technology:The key to finding RFID's ROI 2The key to finding RFID's ROI 3The key to finding RFID's ROI 4
(Date:4/17/2014)... Current Biology on April 17 have discovered ... Brazilian insects, which represent four distinct but related species ... example of an animal with sex-reversed genitalia. , ... animals, Neotrogla is the only example in ... Yoshizawa from Hokkaido University in Japan. , During copulation, ...
(Date:4/17/2014)... the process whereby the genetic information of DNA ... proteins, which have numerous different functions in living ... intermediary during gene expression, by relating the genetic ... in manufacturing proteins. , By examining the ... in an organism at a given time, researchers ...
(Date:4/17/2014)... full of wild animals and plant life, but there,s ... churning away in the soil, decomposing organic matter and ... role these fungi play in ecological systems, their identities ... scientists has generated a genetic map of more than ... was published this week in the Proceedings of ...
Breaking Biology News(10 mins):In sex-reversed cave insects, females have the penises 2Rapid and accurate mRNA detection in plant tissues 2Stanford biologists help solve fungal mysteries 2Stanford biologists help solve fungal mysteries 3
... gases such as CO 2 , which are now known to ... for a number of years. In contrast to the atmosphere, the ... higher. In the global carbon cycle the sea ab-sorbs a proportion ... into the at-mosphere again. About half of the anthropogenic emission ...
... tomography (PET) imaging, seeing is believing: Evaluating a ... typically involves visual interpretation of scans of cancer ... indexone that reflects the reduction of metabolic activity ... responses to first-line chemotherapy, according to a study ...
... Todays Answers, Tomorrows Questions taking place in London ... brings together policymakers, researchers and natural scientists with what ... research in the field of genomics - the Economic ... DNA, genes and chromosomes are often described as ...
Cached Biology News:New ETH Zurich article published in scientific journal 'Nature' 2Quantitative PET imaging finds early determination of effectiveness of cancer treatment 2From GM farm animals to embryonic stem cell research 2From GM farm animals to embryonic stem cell research 3
... The Finnpipette BioControl is a major ... A complete liquid handling system - ... interchangeable tip cone modules. All five ... cone modules fit one handle. The ...
Sulfadimethoxine (CH-2027)...
alpha-N-Catenin Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Bovine Endometrium Epithelial Cells (BEnEpC) (>500,000 cells)...
Biology Products: